The present application may include subject matter related to one or more of the following commonly-owned United States patent applications, each of which was filed on even date herewith and is hereby incorporated herein by reference in its entirety:
The present invention relates generally to pneumatically controlled pumps.
Millions of people receive blood transfusions each year. Although helpful in many cases, blood transfusions have associated risks. Among others, there is a risk that microorganisms capable of causing disease (i.e., pathogens) could pass from the donor blood to the ultimate blood recipient. For example, untreated blood used in a blood transfusion could have pathogens causing the West Nile Virus, or AIDS. It thus is critical for the public health to ensure that transfused blood is substantially free of pathogens.
The medical community has responded to this need by developing various techniques for removing known and unknown pathogens from donated blood. One technique involves mixing precise amounts of a diluted anti-pathogen compound with blood. Some time after mixing, a rinsing process removes the anti-pathogen compound from the blood. One complexity with this process, however, is the fact that the diluted anti-pathogen compound has a very short shelf life (e.g., on the order of about four hours). Accordingly, the diluted anti-pathogen compound must be produced a relatively short time before it is mixed with blood.
The anti-pathogen compound is not easy to handle before it is diluted. To the contrary, it has a very high pH (e.g., on the order of 11.0 or higher) and thus, is highly caustic and toxic. Mere contact with the undiluted solution can melt plastic, or burn flesh. Because of these undesirable properties, the undiluted solution typically is manually diluted by highly trained laboratory technicians that necessarily must be protected from direct contact with it. Consequently, laboratory technicians often are required to wear relatively impermeable protective gear while diluting the solution behind a chemical laminar flowhood. Such a process, however, is inherently slow, imprecise, and costly due to the multitude of safety requirements. Moreover, even with safeguards, diluting the undiluted solution still poses a risk to the laboratory technician.
In connection with developing a pneumatically operated pump cassette with pneumatically operated pump chambers and valves for use in diluting anti-pathogen compound and mixing diluted anti-pathogen compound with blood, a new bezel and associated equipment was invented. In accordance with one aspect of the invention, the bezel is formed by a rigid block having a plurality of cavities on a pumping side of the block. A first depression in the pumping side of the block has at least one of the cavities therein. Ribs either integral to the block or coupled to the block extend up from the depression to form an elevated contour. The ribs allow pneumatic pressure applied through the at least one cavity in the depression to be applied over the elevated contour. A bezel assembly further includes a gasket that fits over the pumping side of the bezel. Positive pressure through the cavity in the depression forces the gasket away from the pumping side and negative pressure through the cavity pulls the gasket against the elevated contour of the ribs.
The elevated contour limits the movement of the gasket into the depression thus reducing the pump stroke. The elevated contour may be in the shape of a mound that increases in height from a perimeter of the depression toward a higher middle of the mound. In accordance with a further aspect of the invention, the ribs extend up from a chamber wall of the depression. Thus, removal of the ribs by milling, or otherwise, leaves an open chamber defined by the chamber wall for delivering a larger pump stroke.
The ribs of an embodiment of the invention, may be arranged to provide a symmetrical grid of air passages. The air passages may be in fluid communication with two cavities in the depression. A further embodiment of the invention may provide the bezel with a second depression. The second depression may be constructed with or without ribs.
In order to provide air pressures through the cavities of the bezel, ports in fluid communication with the cavities are accessible from the back side of the rigid block. In particular embodiments, the ports are hollow tubular structures integral with the rigid block. Further, the inner diameter of a port may be larger in size than the cavity in fluid communication therewith. The ports may provide solvent bondable tubing connections to the bezel.
In the accompanying drawings:
In order to mix two liquids, a first liquid is pumped into a first pump chamber of a pumping apparatus through a channel of the pumping apparatus. A second liquid is pumped from a second pump chamber of the pumping apparatus into either the channel or the first pump chamber, preferably while the first liquid is being pumped into the first pump chamber. In this way, the two liquids are mixed within the pumping apparatus, and, more specifically, within the channel and/or the first pump chamber of the pumping apparatus. The second liquid is preferably pumped in a pulsatile mode in which small quantities of the second liquid are pumped at intervals. The quantity and/or the interval can be dynamically adjusted to result in a predetermined concentration of the two liquids. The contents of the first pump chamber are pumped to a receptacle.
The pumping apparatus may be a disposable pump cassette. The pump cassette typically includes two pump chambers and various valves. The pump chambers and valves are preferably operated pneumatically.
In exemplary embodiments, an anti-pathogen solution is mixed with a red blood cell concentrate (RBCC) to form an incubation solution for reducing pathogens in the RBCC. The anti-pathogen solution is prepared by mixing a caustic anti-pathogen compound known as PEN110™ or INACTINE™, which is an organic solvent with a pH over 11 that is distributed by V.I. Technologies, Inc. of Watertown, Mass., with a buffer solution of sodium phosphate to a predetermined concentration (e.g., 1 part anti-pathogen compound to 99 parts buffer solution), preferably as described in Application D70. For convenience, this mixing of anti-pathogen compound with buffer solution may be referred to hereinafter as “compounding,” and an apparatus that performs such compounding may be referred to hereinafter as a “compounder” or “compounder pump.” The incubation solution is prepared by mixing the anti-pathogen solution with the RBCC to a predetermined concentration (e.g., 1 part anti-pathogen solution to 9 parts RBCC), as described below. For convenience, this mixing of anti-pathogen solution with RBCC may be referred to hereinafter as “blood processing,” and an apparatus that performs such blood processing may be referred to hereinafter as a “blood pump.”
System Overview
The process controller 120 coordinates the actions of the compounder pump 102, the blood pumps 104, and the operator throughout the various mixing operations, as described in greater detail in Application D72. The process controller 120 initiates high level embedded commands within the pumps to move and mix the fluids. The process controller 120 instructs the operator through the setup and teardown of each process through the user interface 116. The user interface 116 is also used to inform the operator of any anomalies that may occur during mixing operations.
When the blood processing system 100 is operating from the uninterruptible power supply 128 and at other appropriate times, the process controller 120 will prevent compounding and other pump operations from starting, although the pumps will generally be allowed to complete any ongoing operations. Furthermore, if the process controller fails, the pumps have internal logic for safely completing or terminating any ongoing operations.
Blood Disposables
The process controller 120 coordinates blood processing for an entire bank of five blood pumps 104 at a time. Specifically, five pump cassettes, each connected to a RBCC container and an incubation bag for receiving the incubation solution, are loaded respectively into the five blood pumps 104. The five pump cassettes are preferably connected by a single working solution inlet tube to the working solution container so that all five blood pumps draw working solution from the single working solution container.
For convenience, the five interconnected pump cassettes along with their respective incubation bags and various plastic tubing may be referred to hereinafter as a “blood disposables set.” The blood disposables set is preferably used for a single blood processing cycle and is then discarded. The blood disposables set is described in greater detail in Application D85.
Among other things, the pump cassette 202 includes a working solution inlet port 304, an RBC inlet port 305, a vent port 307, an outlet port 308 and two pumping chambers, namely a working solution chamber 333 and an RBC chamber 334. During blood processing, working solution from the working solution container 112 is drawn into the working solution chamber 333 through the tubing 210 and 212 and the working solution inlet port 304, and is pumped from the working solution chamber 333 into the channel 310 while RBCC from the RBCC container 106 is drawn into the RBC chamber 334 through the RBCC inlet tube 204, the RBCC inlet port 305, and the channel 310. This causes the working solution and RBCC to be mixed within the channel 310 and the RBC chamber 334. The mixture (incubation solution) is pumped from the RBC chamber 334 to the incubation bag 118 through the outlet port 308 and the incubation solution outlet tube 206.
Blood Pump
As discussed above, each blood pump 104 prepares incubation solution by mixing an anti-pathogen solution with RBCC. A disposable pump cassette 202 is used to handle the various fluids. The pump cassette 202 serves as an interface between the blood pump 104, the RBCC container 106, and the incubation bag 118 so that no working solution, RBCC, or incubation solution comes into actual contact with the components of the blood pump 104. The blood pump 104 preferably uses pneumatics to operate the pump cassette 202 as well as other components, as discussed below.
The blood pump 104 produces the incubation solution by causing working solution to be drawn into the working solution chamber 333 and pumping working solution from the working solution chamber 333 into the channel 310 while drawing RBCC into the RBC chamber 334 through the channel 310. This causes the working solution and RBCC to be mixed within the channel 310 and the RBC chamber 334. The mixture (incubation solution) is pumped from the RBC chamber 334 to the incubation bag 118 through the outlet port 308.
Typically, the working solution is pumped from the working solution chamber 333 using a pulsing technique in which small quantities of working solution are pumped at predetermined intervals and the pulsing of working solution is adjusted periodically using a closed feedback loop in order to produce an incubation solution having a predetermined concentration of working solution, with predetermined limits. Specifically, the working solution is delivered in a pulsatile mode where the pulse width of the exit valve on the working solution chamber is controlled. The fluid valve is pulsed at a pulse width and interval that is predetermined for each pumping stroke and is adjusted stroke-by-stroke according to the amounts of working solution and RBCC pumped, as described below. The blood pump 104 can support pulse widths above some minimum value, and the interval between pulses is increased in order to achieve an effective pulse width below the minimum value.
The blood pump 104 preferably includes a library of generic pump control (N-Pump) functions. The N-Pump library functions are used to perform various generic pumping operations such as, for example, pumping fluid into a chamber of the pump cassette, pumping fluid out of a chamber of the pump cassette, measuring the amount of fluid pumped, performing air detection, and maintaining tank pressures. The blood pump 104 preferably also includes a Fluid Logic Module (FLM) that contains higher level functions that employ the N-Pump library functions to implement application-specific functions (such as specific logic for mixing the working solution with the RBCC to produce the incubation solution).
The blood pump 104 includes one master board connected to two pump boards that together perform the N-Pump and FLM functions. The master board communicates to each of the pump boards via a multi-drop RS 485 bus. Each pump board controls a single pump chamber of the pump cassette 202 and the valves on its board.
Pneumatic Control Assembly
The pneumatic control assembly 410 provides positive and negative air pressure for operating the various other pneumatically controlled components and also acts as the general controller for the blood pump 104. The pneumatic control assembly 410 contains three electromechanical pump module assemblies, namely a tank management module assembly and two chamber module assemblies (one for the working solution pump chamber and one for the RBC pump chamber). Each pump module assembly includes an aluminum manifold, pneumatic valves, pneumatic fittings, a valve interface board, and an electronics board that includes pressure transducers and a dedicated microprocessor. The tank management module assembly handles all communication between the blood pump and the process controller 120, synchronizes pumping of the chamber module assemblies, maintains positive and negative air pressure in various accumulators, seals and unseals the door assembly, engages and disengages the occluders, monitors the door open/closed status, and monitors the air-in-line sensor, as described below. Each chamber management assembly controls a separate one of the pump chambers, and also controls the fluid valves associated with the pump chamber and measures the volume of liquids pumped through the pump chamber.
The tank management module 512 includes an input/output (I/O) board, a CPU board, a valve-interface board, a pneumatic manifold system, pneumatic valves, pressure transducers 2-vent covers (mufflers), stand-offs, and associated tubing and fittings. The tank management module 512 is used to control the pressures in the accumulators 513, a bladder in the door assembly 402, and bladders in the occluder assembly 404. The I/O board contains electrical controls for controlling LEDs that provide status information to the operator. The pressure transducers are used to monitor the pressures of the accumulators 513 and the bladder in the door assembly 402.
In the un-powered state, the pneumatic valve that controls flow to the bladder in the door assembly 402 preferably shuts closed. This prevents the door from being opened in the event of a loss of power.
In the un-powered state, the pneumatic valves that control flow to the bladders in the occluder assembly 404 are preferably channeled to vent. This causes the occluders to occlude the tubing to prevent further flow of fluid through the tubing, as discussed below.
Each chamber module 514 and 515 includes a CPU board, a valve interface board, pneumatic manifold system, pneumatic valves (including a VSO (variable) valve), a VSX chamber (504 and 505 respectively), O-ring, copper mesh, vent cover (muffler), stand-offs, pressure transducers, and associated tubing and fittings. Each chamber module assembly controls the pneumatics for one of the pumping chambers and its associated valves. The VSX chambers 504 and 505 act as reference volumes in order to measure the volume of fluid that is delivered with the FMS system. The pressure transducers are used to monitor the pressure of the VSX chamber, and of the pumping chamber. The positive pneumatic system contains a pressure relief valve to prevent the air pump from pressurizing the positive system to greater than 16.0 psig.
In the un-powered state, all of the pneumatic valves preferably open the fluid valves to the positive pressure line. This ensures that the fluid valves are closed if there is a loss of power.
The blood pump 104 typically includes three microprocessor systems, one on the tank management module 512 and one on each of the chamber modules 514 and 515. These three microprocessor systems monitor each other for normal operation. Each microprocessor system also monitors key internal processes and data for validity. If any of these monitors fail, a failsafe line permits any of the three processors to stop pumping operations, close all of the fluid valves and occluder, and send an anomaly signal to the process controller. If the blood pump 104 detects an anomaly with the commands received from the process controller (e.g., commands received out of sequence), then the blood pump 104 will stop fluid flow and send an anomaly signal to the process controller.
Front Plate Assembly
The front plate assembly 408 includes all necessary pneumatic pathways to interface to the disposable pump cassette 202. The front plate assembly 408 includes, in accordance with the present invention, a bezel and a bezel gasket through which the pump cassette 202 is operated. During operation of the blood pump 104, the pump cassette 202 is positioned in the door assembly 402 and is pressed against the front plate assembly 408 in alignment with the bezel and bezel gasket by a bladder in the door assembly 402, as discussed below. Air lines connected to the bezel from the pneumatic control assembly 410 are used to displace membranes of the bezel gasket to operate the various valves and chambers of the pump cassette 202.
The elevated contour of the ribs 636 limits the pump stroke volume making the ribbed depression suitable for actuating the working solution chamber 333 of the pump cassette 202. The bezel gasket 612 fits over the pumping side of the rigid block sealing the air paths. As positive pressure is applied through one or more cavities into the depression beneath the ribs the gasket membrane 613 covering the ribs is forced away from the pumping side to push against the working solution chamber. When negative pressure is applied through the one or more cavities, the gasket membrane 613 is pulled against the elevated contour of the ribs pulling a small amount of working solution into the working solution chamber.
Referring with greater particularity to the rib structures 636 of the preferred embodiment, it is noted that the rib structures 636 are arranged so as to provide a symmetrical grid of air passages as shown in
The bezel 604 includes a second depression 644 with two cavities 635 for operating the RBC chamber 334 of the pump cassette 202. This depression 644 lacks ribs allowing for a larger volume to be pulled and pushed through the RBC chamber in each stroke as compared to the working solution chamber. The bezel 604 further includes various valve cavities 639 for operating the various valves of the pump cassette 202.
Unlike the blood pump 104, the compounder 102 requires a bezel with two full volume depressions. In accordance with an embodiment of the present invention, the bezel 604 is designed so that the single molded rigid block can also be used as the compounder bezel as shown in
Although the ribs are preferably molded or otherwise integral to the bezel and are removable if needed, a ribbed bezel assembly can alternatively be formed by coupling a rib insert into a depression of the bezel. The rib insert would typically be configured substantially as shown and described above, but would be a separate component. The rib insert could be coupled into a depression of the bezel in any of a variety of ways. For example, the rib insert could be snapped into the depression, for example using tabs on the rib insert that are engaged by corresponding slots on the bezel, or the rib insert could be glued or otherwise attached to the bezel.
Door Assembly
The door assembly 402 mounts to the front plate assembly 408, and provides a means to load and align the disposable pump cassette 202 within the blood pump 104. The door assembly 402 provides a force on the pump cassette 202 against the bezel assembly of the front plate assembly 408 in order to provide sealing of the cassette's fluid paths and valves, as described in greater detail in Application D73. The door assembly 402 includes a special latch system that helps maintain the seal, and also helps prevent accidental opening of the door during blood processing, as described in greater detail in Application D74. The door assembly 402 also provides a surface for the occluders to function against, as described below.
The door assembly is designed to permit single-handed operation, specifically by pulling up on the handle. However, the door latch 703 is designed so that the door cannot be easily opened when the pump cassette is in place in the cassette receptacle 704 with the door closed and the bladder of the piston assembly 711 is inflated. Specifically, the latch portions of the door latch 703 have undercuts that are engaged by recesses in the front plate assembly 408. When the pump cassette is in place in the cassette receptacle 704 with the door closed and the piston assembly 711 is inflated so as to push the pump cassette against the bezel components of the front plate assembly 408, a sufficient force is generated between the door assembly 402 and the front plate assembly 408 to prevent the door handle from being easily lifted.
This door locking mechanism is described in greater detail in Application D74.
Occluder Assembly
The occluder assembly 404 mounts to the back of the front plate assembly 408, and is used to selectively occlude the RBCC inlet tube 204, the incubation solution outlet tube 206, and the working solution distribution tube 212 as needed for testing, blood processing, and protection in the event of a failure. In the blood pump 104, the occluder assembly 404 includes two occluders, one operating on both the RBCC inlet tube 204 and the incubation solution outlet tube 206, and the other operating on the working solution distribution tube 212. The occluders are controlled pneumatically, and can be controlled independently.
In a typical embodiment, each occluder includes an occluder blade that is operated by a flat spring and an inflatable bladder. The occluder blade is coupled to one end of the spring. When the bladder is deflated, the spring extends the occluder blade into an occluding position, which blocks the passage of fluid through the tube(s). When the bladder is inflated, the bladder bends the spring so as to retract the occluder blade from the occluding position, which enables the passage of fluid through the tube(s). In the event of a loss of pneumatics, the occluder defaults to the occluded position so as to prevent fluid from passing through the tubing.
Chassis Components
The chassis components 414 include various mechanical hardware components that are not considered part of the other assemblies. Among other things, the chassis components 414 include the DC air pump 511, a chassis base, a door sensor (and cable), mounting foot grommets, skins (housing), and associated hardware and fasteners. The housing includes a mounting point, on the back of the unit, for the manual piston bladder (door) vent 503.
Pump Cassette Handling
Blood Processing
As discussed above, the compounder 102 and the blood pumps 104 operate under control of the process controller 120. In exemplary embodiments, introduction of the anti-pathogen compound into the RBCC is performed in two stages, a first stage in which the anti-pathogen compound is mixed with buffer solution to a first concentration to form the working solution, and a second stage in which the working solution is mixed with the RBCC to a second concentration to form the incubation solution. The two-stage process is described in more detail in Application D72. A ribbed bezel is preferably used in the blood pumps 104 to limit the amount of working solution that is drawn into the pump cassette during blood processing. Blood processing is described in more detail in Application D71.
The present invention may be embodied in other specific forms without departing from the true scope of the invention. The described embodiments are to be considered in all respects only as illustrative and not restrictive.
Number | Name | Date | Kind |
---|---|---|---|
1133254 | Backus | Mar 1915 | A |
1664576 | Stuart et al. | Apr 1928 | A |
1792906 | Heilos | Feb 1931 | A |
2313551 | Hurlbut | Mar 1943 | A |
2525251 | Willard | Oct 1950 | A |
2526017 | Figg | Oct 1950 | A |
2703055 | Veth et al. | Mar 1955 | A |
2776854 | Billstrom | Jan 1957 | A |
2834504 | Joseph | May 1958 | A |
2902253 | Page | Sep 1959 | A |
3048121 | Sheesley | Aug 1962 | A |
3339956 | Bencene | Sep 1967 | A |
3372501 | Greene | Mar 1968 | A |
3449864 | Prost-Dame et al. | Jun 1969 | A |
3481076 | Bedard | Dec 1969 | A |
3540694 | Cornelius | Nov 1970 | A |
3570486 | Engelsher et al. | Mar 1971 | A |
3722858 | Sugimoto et al. | Mar 1973 | A |
3727882 | Burris et al. | Apr 1973 | A |
3814548 | Rupp | Jun 1974 | A |
3856338 | Johnsson | Dec 1974 | A |
4072934 | Hiller et al. | Feb 1978 | A |
4073521 | Mena | Feb 1978 | A |
4093176 | Contastin | Jun 1978 | A |
4096211 | Rameau | Jun 1978 | A |
4161264 | Malmgren et al. | Jul 1979 | A |
4212589 | Bosio | Jul 1980 | A |
4230300 | Wiltse | Oct 1980 | A |
4247018 | Credle | Jan 1981 | A |
4431425 | Thompson et al. | Feb 1984 | A |
4468219 | George et al. | Aug 1984 | A |
4479760 | Bilstad et al. | Oct 1984 | A |
4479761 | Bilstad et al. | Oct 1984 | A |
4479762 | Bilstad et al. | Oct 1984 | A |
4576211 | Valentini et al. | Mar 1986 | A |
4623450 | Vantard et al. | Nov 1986 | A |
4634430 | Polaschegg | Jan 1987 | A |
4648868 | Hardwick et al. | Mar 1987 | A |
4650339 | Chetcuti et al. | Mar 1987 | A |
4662540 | Schroter | May 1987 | A |
4662829 | Nehring | May 1987 | A |
4667927 | Oscarsson | May 1987 | A |
4696671 | Epstein et al. | Sep 1987 | A |
4698160 | Haraguchi | Oct 1987 | A |
4718447 | Marshall | Jan 1988 | A |
4721138 | Simonazzi | Jan 1988 | A |
4778451 | Kamen | Oct 1988 | A |
4798580 | DeMeo et al. | Jan 1989 | A |
4804366 | Zdeb et al. | Feb 1989 | A |
4807660 | Aslanian | Feb 1989 | A |
4808161 | Kamen | Feb 1989 | A |
4818186 | Pastrone et al. | Apr 1989 | A |
4826482 | Kamen | May 1989 | A |
4828543 | Weiss et al. | May 1989 | A |
4833922 | Frick et al. | May 1989 | A |
4850978 | Dudar et al. | Jul 1989 | A |
4855714 | Clarkson et al. | Aug 1989 | A |
4925444 | Orkin et al. | May 1990 | A |
4927198 | Fennell et al. | May 1990 | A |
4976162 | Kamen | Dec 1990 | A |
5005604 | Aslanian | Apr 1991 | A |
5006050 | Cooke et al. | Apr 1991 | A |
5045068 | Kawai et al. | Sep 1991 | A |
5051922 | Toral et al. | Sep 1991 | A |
5062774 | Kramer et al. | Nov 1991 | A |
5069792 | Prince et al. | Dec 1991 | A |
5088515 | Kamen | Feb 1992 | A |
5088901 | Brauer | Feb 1992 | A |
5098262 | Wecker et al. | Mar 1992 | A |
5098371 | Juji et al. | Mar 1992 | A |
5113904 | Aslanian | May 1992 | A |
5116316 | Sertic et al. | May 1992 | A |
5122116 | Kriesel et al. | Jun 1992 | A |
5146414 | McKown et al. | Sep 1992 | A |
5150796 | Pierson | Sep 1992 | A |
5156186 | Manska | Oct 1992 | A |
5167837 | Snodgrass et al. | Dec 1992 | A |
5178182 | Kamen | Jan 1993 | A |
5186333 | Pierson et al. | Feb 1993 | A |
5197787 | Matsuda et al. | Mar 1993 | A |
5255072 | Mikasa et al. | Oct 1993 | A |
5267956 | Beuchat | Dec 1993 | A |
5272646 | Farmer | Dec 1993 | A |
5279504 | Williams | Jan 1994 | A |
5290076 | Smith | Mar 1994 | A |
5292306 | Wynkoop et al. | Mar 1994 | A |
5294157 | Smith et al. | Mar 1994 | A |
5302093 | Owens et al. | Apr 1994 | A |
5325884 | Mirel et al. | Jul 1994 | A |
5330426 | Kriesel et al. | Jul 1994 | A |
5336053 | Wynkoop | Aug 1994 | A |
D350823 | Lanigan | Sep 1994 | S |
5350357 | Kamen et al. | Sep 1994 | A |
5351686 | Steuer et al. | Oct 1994 | A |
5355890 | Aguirre et al. | Oct 1994 | A |
5378126 | Abrahamson et al. | Jan 1995 | A |
5384714 | Kidd | Jan 1995 | A |
5385540 | Abbott et al. | Jan 1995 | A |
5401059 | Ferrario | Mar 1995 | A |
5408420 | Slocum et al. | Apr 1995 | A |
5411472 | Steg et al. | May 1995 | A |
5421823 | Kamen et al. | Jun 1995 | A |
5423738 | Robinson et al. | Jun 1995 | A |
5428527 | Niemi | Jun 1995 | A |
5429485 | Dodge | Jul 1995 | A |
5431626 | Bryant et al. | Jul 1995 | A |
5438510 | Bryant et al. | Aug 1995 | A |
5439355 | Jimison et al. | Aug 1995 | A |
5463228 | Krause | Oct 1995 | A |
5474683 | Bryant et al. | Dec 1995 | A |
5478337 | Okamoto et al. | Dec 1995 | A |
5482440 | Dennehey et al. | Jan 1996 | A |
5558255 | Sancoff et al. | Sep 1996 | A |
5575310 | Kamen et al. | Nov 1996 | A |
5578012 | Kamen et al. | Nov 1996 | A |
5579244 | Brown | Nov 1996 | A |
5584671 | Schweitzer, Jr. et al. | Dec 1996 | A |
5588816 | Abbott et al. | Dec 1996 | A |
5593290 | Greisch et al. | Jan 1997 | A |
5628908 | Kamen et al. | May 1997 | A |
5634896 | Bryant et al. | Jun 1997 | A |
5638737 | Mattson et al. | Jun 1997 | A |
5647391 | Chan et al. | Jul 1997 | A |
5649810 | Schweitzer, Jr. et al. | Jul 1997 | A |
5651775 | Walker et al. | Jul 1997 | A |
5681285 | Ford et al. | Oct 1997 | A |
5713865 | Manning et al. | Feb 1998 | A |
5716343 | Kriesel et al. | Feb 1998 | A |
5755683 | Houle et al. | May 1998 | A |
5776103 | Kriesel et al. | Jul 1998 | A |
5795328 | Barnitz et al. | Aug 1998 | A |
5808181 | Wamsiedler et al. | Sep 1998 | A |
5816779 | Lawless et al. | Oct 1998 | A |
5823026 | Finke | Oct 1998 | A |
5837905 | Strauss et al. | Nov 1998 | A |
5868162 | Dickerson, Jr. | Feb 1999 | A |
5879328 | Holmberg et al. | Mar 1999 | A |
5883299 | Green et al. | Mar 1999 | A |
5935105 | Manning et al. | Aug 1999 | A |
5938634 | Packard | Aug 1999 | A |
5965821 | Grudzien | Oct 1999 | A |
5989423 | Kamen et al. | Nov 1999 | A |
6022483 | Aral | Feb 2000 | A |
6041801 | Gray et al. | Mar 2000 | A |
6065941 | Gray et al. | May 2000 | A |
6070761 | Bloom et al. | Jun 2000 | A |
6109881 | Snodgrass et al. | Aug 2000 | A |
6136586 | Budowsky | Oct 2000 | A |
6210361 | Kamen et al. | Apr 2001 | B1 |
6223130 | Gray et al. | Apr 2001 | B1 |
6234997 | Kamen et al. | May 2001 | B1 |
6245570 | Grimm et al. | Jun 2001 | B1 |
6264458 | Marcuz et al. | Jul 2001 | B1 |
6302653 | Bryant et al. | Oct 2001 | B1 |
6343614 | Gray et al. | Feb 2002 | B1 |
6364857 | Gray et al. | Apr 2002 | B1 |
6382923 | Gray | May 2002 | B1 |
6416293 | Bouchard et al. | Jul 2002 | B1 |
6464667 | Kamen et al. | Oct 2002 | B1 |
6485263 | Bryant et al. | Nov 2002 | B1 |
6503062 | Gray et al. | Jan 2003 | B1 |
6520747 | Gray et al. | Feb 2003 | B2 |
6527758 | Ko | Mar 2003 | B2 |
6604908 | Bryant et al. | Aug 2003 | B1 |
6663359 | Gray et al. | Dec 2003 | B2 |
6709417 | Houle et al. | Mar 2004 | B1 |
6726656 | Kamen et al. | Apr 2004 | B2 |
6749403 | Bryant et al. | Jun 2004 | B2 |
6790014 | Bowen | Sep 2004 | B2 |
6877713 | Gray et al. | Apr 2005 | B1 |
7011742 | Rosiello | Mar 2006 | B2 |
20030229302 | Robinson et al. | Dec 2003 | A1 |
20040054251 | Liotta | Mar 2004 | A1 |
20040091374 | Gray | May 2004 | A1 |
20050230292 | Beden et al. | Oct 2005 | A1 |
Number | Date | Country |
---|---|---|
WO 8706119 | Oct 1987 | WO |
WO 9422566 | Oct 1994 | WO |
WO 9910028 | Mar 1999 | WO |
WO 0118396 | Mar 2001 | WO |
WO 03086509 | Oct 2003 | WO |
Number | Date | Country | |
---|---|---|---|
20050095154 A1 | May 2005 | US |